Creative Planning Acquires 39,919 Shares of Geron Co. (NASDAQ:GERN)

Creative Planning raised its holdings in shares of Geron Co. (NASDAQ:GERN) by 114.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 74,947 shares of the biopharmaceutical company’s stock after purchasing an additional 39,919 shares during the quarter. Creative Planning’s holdings in Geron were worth $318,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of GERN. National Bank of Canada FI lifted its position in Geron by 1,200.0% during the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,000 shares during the last quarter. Crewe Advisors LLC lifted its holdings in shares of Geron by 870.0% in the 1st quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 8,700 shares during the last quarter. Kingsview Wealth Management LLC bought a new stake in shares of Geron in the 1st quarter worth about $34,000. American Trust bought a new stake in shares of Geron in the 1st quarter worth about $38,000. Finally, CIBC Asset Management Inc lifted its holdings in shares of Geron by 32.7% in the 2nd quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 3,805 shares during the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Stock Down 2.6 %

Shares of NASDAQ:GERN opened at $4.06 on Friday. The firm’s 50 day moving average price is $4.45 and its 200 day moving average price is $4.23. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of -11.60 and a beta of 0.50. Geron Co. has a fifty-two week low of $1.64 and a fifty-two week high of $5.34. The company has a quick ratio of 3.60, a current ratio of 3.61 and a debt-to-equity ratio of 0.12.

Geron (NASDAQ:GERN) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The company had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $0.34 million. During the same quarter last year, the company earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 2941.4% on a year-over-year basis. As a group, equities research analysts predict that Geron Co. will post -0.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on GERN shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Geron in a research note on Friday, August 9th. StockNews.com raised shares of Geron to a “sell” rating in a research note on Monday, August 5th. Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a research note on Monday, September 9th. Leerink Partners started coverage on shares of Geron in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target on the stock. Finally, Scotiabank started coverage on shares of Geron in a research note on Wednesday. They issued a “sector outperform” rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Geron currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.94.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.